An Open-label, Two-part Study of the Disposition and Absolute Bioavailability of [14C]-LY3549492 in Healthy Participants
Latest Information Update: 02 Apr 2024
At a glance
- Drugs LY 3549492 (Primary) ; LY 3549492 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 27 Mar 2024 Status changed from recruiting to completed.
- 09 Jan 2024 New trial record